HLA and cancer
Mechanisms of loss of HLA class I expression on colorectal tumor cells
Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line
Molecular and functional phenotypes of melanoma cells with abnormalities in HLA Class I antigen expression
Characterization of a gastric tumor cell line defective in MHC class I inducibility by both α- and γ-interferon
Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro
HLA-G transcription studies during the different stages of normal and malignant hematopoiesis
Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells
HLA-A*2607: sequence of a novel A*26 subtype predicted by DNA typing which shares the MA2.1 epitope with A*02, B*57 and B*58
The presence of HLA-A*2403 and HLA-B*1512 on the same haplotype in a Thai family
On the sequence of A*3101
Complete cDNA sequence of B*4406, an HLA-B allele containing sequences of B*5101 and B*4402
Full cDNA of a novel HLA-B39 subtype, B*39061
Description of a modified sequencing strategy and the molecular characterization of HLA-B*8201
DNA typing of Cw*14 alleles in Japanese and the corrected sequence of Cw*1402
HLA class I polymorphism and the susceptibility to malignant melanoma
Identification of a DRB1*0405 variant (DRB1*04052) using the PCR-RFLP method
Nomenclature for factors of the HLA system, update March 1996